XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Long-Term Investments (Tables)
 6 Months Ended
Jun. 30, 2023
Long-Term Investments [Abstract]  
Schedule of Ownership Percentages of Investee The ownership percentages of each investee are listed as follows:
   Ownership percentage    
   June 30,   December 31,   Accounting
Name of related party  2023   2022   treatments
Braingenesis Biotechnology Co., Ltd.   0.22%   0.22%  Cost Method
Genepharm Biotech Corporation   0.92%   0.92%  Cost Method
BioHopeKing Corporation   8.03%   8.03%  Cost Method
BioFirst Corporation   21.77%   21.77%  Equity Method
Rgene Corporation   28.85%   28.85%  Equity Method
Schedule of Extent the Investee Relies The extent the investee relies on the company for its business are summarized as follows:
Name of related party  The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.  No specific business relationship
Genepharm Biotech Corporation  No specific business relationship
BioHopeKing Corporation  Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation  Loaned from investee and provides research and development support service
Rgene Corporation  Collaborating with the Company to develop and commercialize drugs

 
Schedule of Long-Term Investment The extent the investee relies on the company for its business are summarized as follows:
   June 30,
2023		   December 31,
2022		 
   (Unaudited)     
Non-marketable Cost Method Investments, net        
Braingenesis Biotechnology Co., Ltd.  $7,081   $7,169 
Genepharm Biotech Corporation   21,617    21,887 
BioHopeKing Corporation   803,008    813,014 
Sub total   831,706    842,070 
Equity Method Investments, net          
BioFirst Corporation   
-
    
-
 
Rgene Corporation   
-
    
-
 
Total  $831,706   $842,070 
Schedule of Balance Sheet Balance Sheet
    June 30,
2023		     December 31,
2022		  
    (Unaudited)        
Current Assets   $ 1,727,649     $ 1,543,152  
Non-current Assets     644,654       739,472  
Current Liabilities     3,375,670       2,663,051  
Non-current Liabilities     367,002       103,447  
Stockholders’ Equity (Deficit)     (1,370,369 )     (483,874 )
   June 30,
2023		   December 31,
2022		 
   (Unaudited)     
Current Assets  $56,752   $68,302 
Noncurrent Assets   250,077    303,893 
Current Liabilities   2,416,522    2,478,868 
Noncurrent Liabilities   1,268    2,441 
Shareholders’ Deficit   (2,100,961)   (2,109,114)
Schedule of Statement of Operation Statement of Operations
   Six months Ended
June 30,		 
   2023   2022 
   (Unaudited) 
Net sales  $
-
   $15,398 
Gross profit   
-
    3,375 
Net loss   (788,788)   (872,254)
Share of losses from investments accounted for using the equity method   
-
    
 
 

 

    Six months Ended
June 30,		  
    2023     2022  
    (Unaudited)  
Net sales   $ -     $ -  
Gross Profit     -       -  
Net loss     (155,873 )     (295,517 )
Share of loss from investments accounted for using the equity method     -       -  
Schedule of Equity Investments The components of losses on equity investments for each period were as follows:
   Six months Ended
June 30,		 
   2023   2022 
   (Unaudited) 
Share of equity method investee losses  $
       -
   $
         -